8V8.F GENETIC ANALYSIS NK -60

Healthcare Biotechnology Frankfurt Exchange
0.0338 EUR
Close of Nov 11, 2026
0.0020 0.0820
Market cap
EUR 2.34M
P/E
-
P/B
1.18x
ROE
-68.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8V8.F undervalued?

Graham number

The Graham number of GENETIC ANALYSIS NK -60 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENETIC ANALYSIS NK -60 fundamental analysis

No fundamental analysis for GENETIC ANALYSIS NK -60 yet.

GENETIC ANALYSIS NK -60 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENETIC ANALYSIS NK -60

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome resear…

Full company profile